World Journal of
Pharmacy and Medical Science

ISSN: 3049-3501
Impact Factor: 5.157
CODEN (USA): WJPMAA

Review Article
2026 Volume 2, Issue 9
Page No.: 06-14

MANAGEMENT OF CHEMOTHERAPY-INDUCED TOXICITY: EMERGING AND NOVEL THERAPEUTIC APPROACHES – A REVIEW

Savidhan Sudarshan Kamble*, Shaikh Sadiya Hamid, Manthan B. Mirkale, Akshay Anand Gupta, Dr. Prajakta Kelgaonkar

Student, Pharm.D 3rd Year, Department of Pharmacy Practice, Channabasweshwar College of Pharmacy, Latur, Maharashtra, India.

Article Received: 05 July 2026 Article Review: 26 July 2026 Article Accepted: 16 August 2026

***Corresponding Author: Savidhan Sudarshan Kamble**
Student, Pharm.D 3rd Year, Department of Pharmacy Practice, Channabasweshwar College of Pharmacy, Latur, Maharashtra, India.
DOI: https://doi.org/10.5281/zenodo.22161516

How to cite this Article: Savidhan Sudarshan Kamble, Shaikh Sadiya Hamid, Manthan B. Mirkale, Akshay Anand Gupta, Dr. Prajakta Kelgaonkar (2026). MANAGEMENT OF CHEMOTHERAPY-INDUCED TOXICITY: EMERGING AND NOVEL THERAPEUTIC APPROACHES – A REVIEW. World Journal of Pharmacy and Medical Science, 2(9): 06-14.

ABSTRACT
Chemotherapy remains an important component of cancer treatment, but its benefits may be limited by adverse effects on normal tissues. Because many cytotoxic medicines interfere with processes that are also active in healthy, rapidly renewing cells, patients can develop hematological, gastrointestinal, cardiovascular, neurological, renal, hepatic, dermatological and reproductive complications. The severity of these effects differs between patients and may be influenced by the drug, dose, cumulative exposure, organ function, co-morbidities, concomitant medicines and inherited differences in drug handling. Toxicity can reduce quality of life and may lead to dose modification, treatment delay, hospitalization or discontinuation. Conventional management therefore emphasizes prevention, early recognition, monitoring and supportive care. At the same time, oncology is increasingly exploring approaches that may predict toxicity or selectively protect normal tissues before serious injury develops. Pharmacogenomics, targeted drug delivery, nanotechnology, cytoprotective agents, immunotherapy, microbiome-based strategies, stem-cell support and artificial intelligence are among the emerging areas of interest. This review discusses the mechanisms, major clinical manifestations, risk factors, prevention and management of chemotherapy-induced toxicity and summarizes selected novel approaches. The contribution of clinical pharmacists to medication review, adverse-drug-reaction monitoring, interaction assessment, supportive-care optimization and patient counselling is also discussed.[1–4]

KEYWORDS: Chemotherapy; chemotherapy-induced toxicity; adverse drug reactions; supportive care; pharmacogenomics; nanotechnology; targeted drug delivery; cytoprotection; precision medicine; clinical pharmacist.

1. INTRODUCTION

Cancer remains a major health challenge worldwide, and chemotherapy continues to have an important role in the treatment of many solid tumors and hematological malignancies. Depending on the disease, stage and treatment objective, chemotherapy may be used with curative intent, after surgery as adjuvant treatment, before surgery as neoadjuvant treatment, or as part of palliative care. It may also be combined with radiotherapy, hormonal therapy, targeted medicines or immunotherapy. Although newer treatment strategies have expanded the therapeutic options available to patients, conventional chemotherapy remains an important part of many treatment protocols.[1–4]

The major limitation of conventional cytotoxic therapy is that the distinction between malignant and normal rapidly dividing cells is incomplete. Drugs that interfere with DNA replication, mitosis or other cellular processes can therefore affect bone marrow, gastrointestinal mucosa, hair follicles and reproductive tissues. The resulting injury may occur during treatment or may become apparent later, depending on the medicine, exposure and organ involved.[3,4]

Chemotherapy-induced toxicity is clinically important because it is not limited to temporary discomfort. Severe neutropenia can increase the risk of infection, thrombocytopenia can cause bleeding, and anemia can worsen fatigue and functional limitation. Gastrointestinal toxicity may result in dehydration and poor nutritional intake, while neuropathy can persist beyond completion of therapy. Cardiac, renal and hepatic injury may influence future treatment options and long-term health.[3,4,9–11]

Not every patient receiving the same chemotherapy regimen develops toxicity to the same degree. Age, nutritional status, baseline organ function, previous treatment, cumulative dose, co-morbid disease and concomitant medicines can alter risk. Genetic variation may also influence drug metabolism, transport and tissue susceptibility. These differences have increased interest in individualized risk assessment and pharmacogenomics.[12,13]

The management of toxicity has traditionally focused on supportive measures, monitoring and modification of chemotherapy when necessary. Antiemetic treatment, hydration, growth-factor support, oral care, nutritional support and careful laboratory monitoring can reduce complications and help patients complete treatment. However, these measures do not always prevent the underlying tissue injury. Consequently, current research is also directed towards targeted drug delivery, cytoprotection, genetic prediction, microbiome-based approaches and digital methods for earlier identification of high-risk patients.[5,6,12–18]

2. Overview and Classification of Chemotherapy-Induced Toxicity

Chemotherapy-induced toxicity can be classified according to the organ system involved, the severity of the adverse event and the time at which it develops. Timing is clinically useful because some toxicities are expected shortly after treatment, whereas others are cumulative or delayed. Recognizing the pattern can support appropriate monitoring and timely intervention.

Pattern	Typical examples	Clinical significance
Acute	Nausea/vomiting, hypersensitivity reactions, infusion-related effects, electrolyte changes	May require prompt symptomatic treatment or treatment interruption
Early-delayed	Neutropenia, thrombocytopenia, mucositis, diarrhea	Often requires laboratory monitoring and supportive care
Late	Peripheral neuropathy, cardiotoxicity, nephrotoxicity, selected hepatic injury	May become persistent or dose-limiting
Long-term	Infertility, persistent organ dysfunction and selected survivorship effects	Important for quality of life and long-term follow-up

Toxicity should also be graded in a consistent manner. The Common Terminology Criteria for Adverse Events provides a standardized framework for describing severity and is useful when comparing treatment cycles and communicating decisions between members of the oncology team.[19]

2.1 Factors Influencing the Risk of Toxicity

The risk of adverse effects is determined by a combination of treatment-related and patient-related factors. Drug class, dose intensity, administration schedule and cumulative exposure are important treatment factors. Patient factors include age, nutritional status, renal and hepatic function, previous chemotherapy or radiotherapy, baseline blood counts and co-morbid conditions. Polypharmacy can add another layer of risk because concomitant medicines may alter drug exposure or increase overlapping toxicities.[3,4,12]

Organ reserve is particularly important. A patient with reduced renal function may have greater exposure to a medicine that is predominantly cleared by the kidneys, while pre-existing cardiac disease may increase concern with potentially cardiotoxic agents. Careful assessment before each cycle therefore provides an opportunity to identify modifiable risks before treatment is continued.

2.2 Acute, Cumulative and Delayed Toxicity

Some toxicities occur soon after drug administration and may be related to immediate pharmacological effects. Others become more evident after repeated cycles because injury accumulates faster than the tissue can recover. Delayed toxicity is especially important in the nervous, cardiovascular and reproductive systems because symptoms may persist after the anticancer treatment has ended. Long-term follow-up is therefore an important component of cancer care rather than an activity limited to the treatment period.[3,4,9,10]

3. Mechanisms of Chemotherapy-Induced Toxicity

Chemotherapy toxicity is multifactorial. Direct DNA injury, oxidative stress, inflammatory signaling, mitochondrial dysfunction, apoptosis and altered cellular repair mechanisms can act together. The contribution of each mechanism varies with the drug and the affected tissue. Genetic differences can further influence exposure and susceptibility.[3,4,12–15,20–23]

3.1 DNA Damage

Many cytotoxic drugs exert their anticancer action by interfering with DNA integrity or replication. Alkylating agents and platinum compounds can form DNA cross-links, while topoisomerase inhibitors interfere with DNA processing and repair. These mechanisms are useful

against malignant cells but can also injure normal proliferating tissues. Bone-marrow suppression and gastrointestinal mucosal injury are therefore common manifestations of cytotoxic treatment.[3,14,20]

The extent of damage depends on both the amount of exposure and the ability of a tissue to repair injury. Cells with a high rate of proliferation are particularly vulnerable. This explains why tissues that normally regenerate quickly can show toxicity even when other organs remain relatively unaffected.

3.2 Oxidative Stress and Reactive Oxygen Species

Several anticancer medicines can increase the formation of reactive oxygen species. When antioxidant defenses are insufficient, oxidative stress can damage lipids, proteins, DNA and mitochondrial structures. This mechanism is particularly relevant to anthracycline-associated cardiac injury and has also been implicated in renal and neurological damage.[15,21]

Oxidative injury may interact with other pathways rather than acting alone. Mitochondrial dysfunction can generate additional reactive species, while inflammation can further increase cellular stress. This interaction helps explain why toxicity may become more pronounced with cumulative exposure.

3.3 Inflammatory Pathways

Chemotherapy can activate inflammatory signaling and increase mediators such as tumor necrosis factor-α and interleukins. The resulting response contributes to mucosal injury, gastrointestinal symptoms and delayed tissue recovery. Inflammation may also amplify the effects of direct DNA and oxidative damage.[15,20]

3.4 Mitochondrial Dysfunction

Mitochondria are important sources of cellular energy and regulators of cell survival. Injury can reduce ATP production, disturb calcium balance and increase oxidative stress. These effects are particularly relevant in organs with high energy requirements, including the heart and nervous system. Mitochondrial injury can also activate pathways leading to programmed cell death.[15]

3.5 Apoptosis and Loss of Normal Cells

Chemotherapy is intended to induce death of malignant cells, but normal cells may also undergo apoptosis when exposed to sufficient drug concentrations. Loss of normal cells in rapidly renewing tissues contributes to mucositis, alopecia and marrow suppression.[14,15]

3.6 Genetic Susceptibility and Pharmacogenomics

Patients exposed to the same medicine may have markedly different toxicity because genetic variation can affect drug metabolism, transport and cellular sensitivity. Pharmacogenomic research aims to identify these differences before severe toxicity occurs. In selected treatment settings, genotype information may support dose selection or identification of patients who need an alternative approach.[12,13]

3.7 Immune-Mediated Tissue Injury

Immune-based cancer treatments can produce toxicities that differ from those associated with conventional cytotoxic drugs. Excessive immune activation may affect the skin, gastrointestinal tract, liver, lungs and endocrine organs. Recognition is important because immune-mediated toxicity may require a different management strategy from direct cytotoxic injury.[23]

4. Major Types of Chemotherapy-Induced Toxicity

The clinical pattern depends on the drug, dose, duration of exposure and vulnerability of the affected tissue. Several toxicities are particularly relevant because they may become dose-limiting or interfere with treatment continuity.

System	Common manifestations	Main clinical concern
Hematological	Neutropenia, anemia, thrombocytopenia	Infection, bleeding, fatigue and treatment delay
Gastrointestinal	Nausea/vomiting, mucositis, diarrhea, constipation	Dehydration, malnutrition and reduced treatment tolerance
Cardiovascular	Cardiomyopathy, arrhythmias, reduced cardiac function	Potentially serious or cumulative organ injury
Neurological	Peripheral neuropathy, sensory changes, pain	Functional impairment and persistent symptoms
Renal	Acute kidney injury, electrolyte abnormalities	Reduced clearance and dose-limiting dysfunction
Hepatic	Raised liver enzymes, hepatocellular/cholestatic injury	Altered drug handling and treatment modification
Dermatological	Alopecia, rash, pigmentation, hand-foot reactions	Discomfort, body-image effects and adherence concerns
Reproductive	Reduced ovarian/testicular function, infertility	Potential long-term effect on fertility

4.1 Hematological Toxicity

Myelosuppression is one of the most frequent dose-limiting effects of cytotoxic therapy. Neutropenia is clinically important because infection can progress rapidly in patients with low neutrophil counts. Thrombocytopenia increases the risk of bleeding, while

anemia may contribute to fatigue, weakness and reduced exercise tolerance. Monitoring of blood counts before and during treatment is therefore essential.[6,30]

Management depends on the severity and clinical context. In selected patients, growth-factor support can reduce the risk or duration of neutropenia. Treatment delay or dose adjustment may be required when blood counts have not recovered sufficiently for the next cycle. Patients should also receive clear instructions about symptoms such as fever or unexplained bleeding that require prompt assessment.

4.2 Gastrointestinal Toxicity

Nausea and vomiting are among the most commonly recognized adverse effects of chemotherapy. Their severity depends on the emetogenic potential of the regimen as well as patient-specific factors. Poor control may lead to dehydration, electrolyte imbalance, reduced oral intake and reluctance to continue treatment. Mucositis, diarrhea, constipation and appetite loss may occur simultaneously.[5,7]

Prevention is generally more effective than waiting for severe symptoms. Antiemetic therapy should be matched to the expected emetogenic risk, while hydration, oral care, nutritional advice and treatment of bowel disturbances should be individualized. Patients should be encouraged to report persistent vomiting, inability to drink or severe diarrhea early.

4.3 Cardiovascular Toxicity

Cardiotoxicity is an important concern with selected anticancer medicines, particularly anthracyclines. Injury may appear as an asymptomatic reduction in ventricular function or progress to clinically evident heart failure. Risk is influenced by cumulative exposure and baseline cardiovascular status.[10,17]

A practical approach includes baseline cardiovascular assessment in patients at risk and appropriate monitoring during treatment. When cardiac function deteriorates, continuation of the offending therapy should be reassessed in relation to the expected anticancer benefit and available alternatives.

4.4 Neurological Toxicity

Chemotherapy-induced peripheral neuropathy commonly presents as numbness, tingling, burning pain or altered sensation in the hands and feet. Severe symptoms may interfere with walking, sleep, fine motor tasks and daily activities. Neuropathy may continue after chemotherapy has ended, making early recognition important.[9]

Patients should be asked about sensory symptoms during treatment rather than waiting for them to become severe. Dose modification or treatment adjustment may be considered when neuropathy becomes clinically significant. Symptom management should also address pain and functional limitations.

4.5 Renal Toxicity

The kidneys are vulnerable to selected chemotherapy agents, with cisplatin being a well-known example. Renal injury may involve tubular damage, reduced renal function and electrolyte abnormalities. Hydration, renal-function assessment and appropriate dose adjustment are important components of prevention and monitoring.[11]

Renal function is also relevant because impaired clearance can increase exposure to medicines that depend on the kidney for elimination. A change in serum creatinine or estimated renal function may therefore influence both chemotherapy and supportive-medication decisions.

4.6 Hepatic Toxicity

The liver is involved in the metabolism and elimination of many anticancer medicines and supportive treatments. Hepatic injury may appear as elevations in liver enzymes or as clinically significant hepatocellular or cholestatic dysfunction. Interpretation should consider baseline liver disease, concomitant medicines and the overall clinical picture.[3,4]

Monitoring liver function can identify changes before severe injury occurs. When abnormalities become clinically important, the treatment team may need to investigate alternative causes and reassess drug selection or dose.

4.7 Dermatological Toxicity

Alopecia, rash, pigmentation changes and hand-foot reactions can have a substantial psychological and functional effect even when they are not medically life-threatening. Changes in appearance may affect body image and confidence, while painful skin reactions can interfere with walking or routine activities.[8]

Patients benefit from anticipatory counselling and practical skin-care advice. Early reporting allows clinicians to distinguish mild expected changes from reactions that require treatment modification.

4.8 Reproductive Toxicity

Some chemotherapy regimens can impair ovarian or testicular function and may affect future fertility. The risk depends on the specific medicine, dose and patient factors. Because fertility preservation may need to be arranged before treatment starts, discussion should occur early whenever a meaningful risk is anticipated.

Reproductive counselling should be approached sensitively and should include the possibility of temporary or permanent effects. Long-term survivorship care should also address reproductive concerns when relevant.

5. Risk Assessment and Prevention of Toxicity

The most effective toxicity strategy is often prevention. Before treatment, the oncology team can establish a

baseline profile including blood counts, renal and hepatic function, cardiovascular status where appropriate, previous treatment exposure and current medicines. This baseline makes it easier to recognize clinically meaningful changes during subsequent cycles.

Medication reconciliation is particularly important because patients may use prescription medicines, over-the-counter products or herbal preparations that are not always reported. Overlapping toxicities and interactions may increase risk. A structured review can identify avoidable problems before chemotherapy begins.[27]

Prevention should also include patient education. Patients should know which symptoms are expected, which are potentially serious and when to contact the treatment team. Written instructions can be useful because information given during a chemotherapy visit may be difficult to remember later.

Preventive step	Examples	Expected benefit
Baseline assessment	CBC, renal/liver function, relevant cardiac assessment	Identifies pre-existing abnormalities and establishes a reference
Medication reconciliation	Prescription, OTC and herbal medicines	Reduces interaction and duplicate-toxicity risks[27]
Regimen-specific prophylaxis	Antiemetics, hydration, selected growth-factor support	Prevents predictable complications[5,6,30]
Patient education	Fever, bleeding, dehydration and severe symptom warnings	Promotes early reporting
Ongoing monitoring	Symptoms, laboratory values and organ function	Allows earlier intervention[19]

6. Conventional Management Strategies

The practical objective of toxicity management is to maintain effective cancer treatment while reducing avoidable harm. Management is usually multidisciplinary and includes prevention, monitoring, symptom control, supportive medicines and chemotherapy modification when necessary.

Strategy	Examples	Purpose
Dose modification	Dose reduction, delay or temporary interruption	Limit severe or persistent toxicity[19]
Supportive care	Antiemetics, analgesia, hydration, oral care	Reduce symptoms and maintain treatment tolerance[5,7]
Hematopoietic support	Selected growth-factor therapy	Reduce risk or duration of selected cytopenias[6,30]
Organ monitoring	CBC, renal/liver function, electrolytes, cardiac assessment	Detect toxicity before it becomes severe
Patient education	Warning signs, adherence and self-care advice	Promote early reporting and safer treatment

6.1 Dose Modification and Monitoring

Dose reduction or treatment delay may be appropriate when toxicity reaches a clinically important grade. Decisions should consider severity, recovery, organ function, treatment intent and the availability of alternatives. Standardized grading helps maintain consistency between cycles.[19]

Monitoring should not be limited to laboratory tests. Patients may develop neuropathy, mucositis, skin changes or functional problems that are not adequately represented by routine blood results. A structured symptom review is therefore necessary alongside laboratory monitoring.

6.2 Antiemetic and Gastrointestinal Support

Antiemetic treatment should be selected according to the emetogenic potential of the chemotherapy regimen and patient risk. Adequate control reduces dehydration, poor intake and treatment-related distress.[5,7] Oral care, hydration and management of diarrhea or constipation should be incorporated when these problems are anticipated.

6.3 Hematopoietic Growth Factors

Growth-factor support can reduce the risk or duration of selected chemotherapy-related cytopenias. Use should be guided by the regimen, risk of febrile neutropenia and patient-specific circumstances rather than applied automatically to every patient.[6,30]

6.4 Nutritional Support and Infection Prevention

Poor appetite, nausea, mucositis and diarrhea can reduce nutritional intake. Early dietary advice and attention to hydration may prevent avoidable deterioration. Patients at increased infection risk should receive practical advice about fever, hygiene and when urgent evaluation is required.

6.5 Oral Care and Mucositis Management

Mucositis can interfere with eating, drinking and oral hygiene. Preventive oral care, regular assessment and

symptom-directed treatment are useful components of supportive care. Patients should be encouraged to report painful oral lesions early so that nutrition and hydration are not compromised.

7. Emerging and Novel Therapeutic Approaches

The direction of research is increasingly shifting from treating toxicity after it appears to predicting risk and reducing exposure of healthy tissues before serious injury develops. The approaches described below are promising, but their clinical maturity is not the same across all areas.

7.1 Targeted Drug Delivery and Nanotechnology

Targeted delivery systems attempt to alter the distribution of anticancer medicines so that more drug reaches the desired site while reducing exposure of normal tissues. Liposomes, polymeric nanoparticles and other carriers can influence circulation time, tissue distribution and drug release.[16,18]

Nanotechnology may also improve the formulation of drugs with unfavorable pharmacokinetic properties. However, successful targeting in experimental models does not always translate into the same degree of benefit in patients. Manufacturing complexity, cost, reproducibility and variable tumor biology remain practical limitations.[16,18]

7.2 Pharmacogenomics and Personalized Therapy

Pharmacogenomics uses inherited genetic information to understand why patients differ in drug response and toxicity. Variation in enzymes, transporters and drug targets can influence exposure or susceptibility. In selected settings, genotype-guided therapy may allow a safer dose or alternative medicine to be selected before serious toxicity develops.[12,13]

The future value of pharmacogenomics depends on the strength of evidence linking a genetic marker with a clinically meaningful decision. Testing should therefore be guided by validated evidence rather than by the assumption that every genetic difference has immediate therapeutic relevance.

7.3 Biomarker-Guided Toxicity Prediction

Beyond inherited genetic variation, biomarkers obtained from blood, tumor tissue or other clinical measurements may help identify patients who are more likely to develop a particular adverse effect. Combining biomarkers with clinical characteristics may improve risk stratification and allow monitoring intensity to be adjusted according to individual risk.

7.4 Biologics and Monoclonal Antibodies

Monoclonal antibodies and other biologic treatments act on defined molecular targets and have expanded the possibilities for selective cancer therapy. Greater target specificity may reduce some nonspecific toxicities associated with conventional cytotoxic therapy, although biologics have their own adverse-effect profiles and can produce infusion, immune or organ-specific reactions.[28]

7.5 Cytoprotective Agents

Cytoprotective agents are intended to reduce injury to selected normal tissues without weakening anticancer activity. Dexrazoxane is an established example used in appropriate settings to reduce anthracycline-associated cardiac injury.[17] The major challenge is maintaining a favorable balance between normal-tissue protection and preservation of antitumor efficacy.

7.6 Immunotherapy Integration

Immune checkpoint inhibitors have changed the treatment of several cancers by enhancing antitumor immune responses. In selected patients they may reduce reliance on conventional chemotherapy, but immune activation can also produce adverse effects involving the skin, bowel, liver, lungs and endocrine organs.[23]

The growing use of immunotherapy means that toxicity assessment must consider the mechanism of the treatment. A symptom such as diarrhea, for example, may represent conventional treatment-related gastrointestinal injury or an immune-mediated inflammatory process, and the distinction affects management.

7.7 Microbiome-Based Approaches

The intestinal microbiome is increasingly recognized as a potential modifier of cancer treatment response and immune activity. Chemotherapy and other anticancer therapies can alter microbial composition, while microbial differences may influence treatment effects and gastrointestinal tolerance. Microbiome modulation is therefore being investigated as a supportive or treatment-enhancing strategy.[24]

The field remains developing, and the effects of specific diets, probiotics or microbiome-directed interventions cannot be assumed to be equivalent. More controlled clinical evidence is needed before routine implementation.

7.8 Stem-Cell Support

Hematopoietic stem-cell transplantation can restore marrow function after intensive treatment in selected hematological malignancies. It is a specialized therapeutic strategy rather than a routine solution for chemotherapy toxicity and requires careful patient selection, conditioning and supportive care.[25]

7.9 Artificial Intelligence and Machine Learning

Artificial intelligence can combine clinical, laboratory, imaging and other patient data to identify patterns that may not be obvious from a single variable. In oncology, machine-learning methods are being explored for risk prediction, treatment planning and clinical decision support.[26]

For toxicity prediction, a useful model would ideally identify high-risk patients early enough for the clinical team to intervene. However, model performance depends on data quality and representativeness. External validation, transparency, bias assessment, privacy and clinician oversight remain essential before widespread clinical use.

Approach	Potential value	Important limitation
Pharmacogenomics	Earlier identification of patients at higher toxicity risk	Testing and evidence vary between medicines[12,13]
Targeted/nano delivery	More selective drug distribution	Targeting, cost and manufacturing challenges[16,18]
Biomarkers	Risk stratification and earlier monitoring	Clinical validation may be limited
Cytoprotection	Protection of selected normal organs	Must not compromise antitumor efficacy[17]
Microbiome strategies	Potential influence on response and GI tolerance	Clinical evidence is still developing[24]
AI/ML	Risk prediction and decision support	Validation, bias, privacy and interpretability[26]

8. Role of the Clinical Pharmacist

Safe chemotherapy requires close coordination between oncologists, nurses, pharmacists and other healthcare professionals. The clinical pharmacist can contribute throughout the treatment pathway, from prescription review and preparation to monitoring, patient education and follow-up.[27]

8.1 Medication Review and Dose Optimization

Pharmacists can review the chemotherapy prescription, dose, schedule and route and consider patient-specific factors such as body surface area, renal and hepatic function, co-morbidities and concomitant medicines. This review can identify dosing problems, contraindications and preventable medication errors.

8.2 Adverse Drug-Reaction Monitoring

Monitoring can include complete blood counts, renal and liver function, electrolytes, cardiac assessment and neurological symptoms, depending on the regimen. Pharmacists can document suspected adverse drug reactions, assess severity and communicate significant findings to the treating team.[27]

8.3 Drug–Drug and Drug–Food Interaction Assessment

Patients with cancer frequently use several supportive and chronic medicines simultaneously. Pharmacists can screen for drug–drug, drug–food and drug–herbal interactions that may increase toxicity or reduce treatment effectiveness. This is particularly relevant when anticoagulants, anti-infectives, analgesics or other medicines with narrow therapeutic margins are used alongside chemotherapy.[27]

8.4 Patient Counselling and Education

Counselling should be practical and individualized. Patients should understand how to take supportive medicines, which symptoms may occur, which warning signs require urgent contact and why laboratory follow-up is necessary. Clear education may encourage earlier reporting and reduce preventable treatment interruptions.

8.5 Supportive-Care Optimization

Pharmacists can help optimize antiemetics, analgesics, hydration, electrolyte replacement, growth-factor support and medicines used for gastrointestinal or mucosal symptoms. The objective is to control symptoms while avoiding unnecessary medicines and additional interactions.[5,6,27]

8.6 Pharmacovigilance and Documentation

Systematic documentation of adverse drug reactions contributes to medication safety and may help identify recurring problems with a regimen. Recording the suspected medicine, timing, severity, management and outcome supports future treatment decisions and improves communication between healthcare professionals.

9. Patient-Centered Care and Quality of Life

Toxicity management should not focus only on laboratory abnormalities. Symptoms such as nausea, pain, neuropathy, fatigue, skin changes and changes in appearance can influence sleep, mobility, work, social interaction and emotional well-being. A patient may therefore consider a toxicity clinically important even when it is not classified as severe by laboratory criteria.

Shared decision-making is particularly relevant when a toxicity becomes persistent or when treatment modification could affect anticancer efficacy. The treatment team should discuss the expected benefit, potential risks and available alternatives in language that the patient can understand. This approach supports adherence while respecting individual priorities.

Patient-reported symptoms can complement objective monitoring. Asking directly about daily functioning, appetite, sleep, pain and sensory changes may reveal clinically meaningful toxicity earlier than routine laboratory testing alone.

10. Future Perspectives

Future chemotherapy care is likely to become more predictive, individualized and integrated. Precision medicine may combine genetic, molecular and clinical

information to identify patients who are especially vulnerable before treatment begins.[12,13]

Advanced delivery systems may reduce systemic exposure to normal tissues, while biomarkers and digital monitoring may help identify early changes before toxicity becomes severe. Wearable or remote monitoring technologies may eventually allow selected symptoms and physiological parameters to be followed between clinic visits.

Artificial intelligence may help combine large amounts of clinical data and generate individualized risk estimates, but its usefulness will depend on validation in real-world populations and responsible clinical implementation.[26]

Future research should also address accessibility and cost. A technology that works well in a specialized research setting may have limited value if it is difficult to manufacture, requires unavailable testing or cannot be integrated into routine oncology services. The most useful innovations will therefore be those that demonstrate not only biological promise but also clinical benefit and practical feasibility.

11. Limitations and Challenges

Despite progress in toxicity management, several challenges remain. Many patients receive multiple medicines simultaneously, making it difficult to attribute a symptom to a single drug. Cancer itself can also produce symptoms that resemble treatment toxicity. Accurate assessment therefore requires clinical context rather than relying on a single laboratory result.

Another challenge is the gap between emerging technologies and routine clinical practice. Pharmacogenomic markers may have strong biological associations without yet providing a clear treatment decision, while nanoparticle and targeted-delivery systems may show promising experimental results but face manufacturing and cost barriers. AI models may perform well in one dataset but lose accuracy when applied to different patient populations.

For these reasons, future research should prioritize reproducibility, clinically meaningful endpoints, external validation and patient-centered outcomes. The objective should not simply be to develop more technologies, but to identify interventions that genuinely reduce severe toxicity without reducing the effectiveness of cancer treatment.

12. CONCLUSION

Chemotherapy remains a major component of cancer treatment, but its effects on normal tissues can produce clinically important toxicity across multiple organ systems. The consequences range from temporary symptoms to persistent organ injury and may interfere with treatment continuity, daily functioning and quality of life.[1–4]

Conventional measures such as baseline assessment, dose modification, supportive therapy, laboratory monitoring, nutritional care and patient education remain the practical foundation of toxicity management. Prevention and early recognition are particularly important because severe toxicity may require hospitalization or interruption of effective anticancer treatment.[5,6,19,30]

At the same time, pharmacogenomics, targeted delivery, nanotechnology, cytoprotective strategies, immunotherapy, microbiome research, stem-cell support and artificial intelligence are opening new possibilities for more individualized care.[12,16–18,23–26] These approaches are promising, but their clinical value must be judged by the quality of evidence and their ability to improve patient outcomes.

Clinical pharmacists can strengthen this approach through medication review, interaction assessment, adverse-drug-reaction monitoring, supportive-care optimization, pharmacovigilance and patient counselling.[27] Overall, the future of chemotherapy toxicity management lies in combining effective anticancer treatment with earlier prediction, prevention, selective protection of normal tissues and patient-centered supportive care.

REFERENCES

1. National Cancer Institute. Chemotherapy to treat cancer [Internet]. Bethesda (MD): National Cancer Institute, 2024.
2. World Health Organization. Cancer [Internet]. Geneva: World Health Organization, 2024.
3. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education, 2023.
4. DeVita VT Jr, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 12th ed. Philadelphia: Wolters Kluwer, 2023.
5. Schneider BJ, Aapro MS, Andrews MC, et al. Antiemetics: ASCO guideline update. J Clin Oncol, 2020; 38(24): 2782-2797.
6. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines. Ann Oncol, 2010; 21(Suppl 5): v248-v251.
7. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med, 2008; 358(23): 2482-2494.
8. Lacouture ME. Mechanisms of chemotherapy-induced dermatologic toxicities. Oncology, 2006; 20(5): 15-21.
9. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity. CA Cancer J Clin. 2013;63(6):419-437.

10. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol, 2009; 53(24): 2231-2247.
11. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol, 2003; 23(5): 460-464.
12. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature, 2015; 526(7573): 343-350.
13. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med, 2003; 348(6): 538-549.
14. Wang X, Li Y, Luo J, et al. DNA damage response pathways in chemotherapy. Nat Rev Cancer, 2009; 9(3): 133-147.
15. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms. Nat Rev Drug Discov, 2009; 8(7): 579-591.
16. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev, 2013; 65(1): 36-48.
17. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin and dexrazoxane. Cancer, 2003; 97(11): 2869-2879.
18. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007; 2(12): 751-760.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda (MD): National Cancer Institute, 2017.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell, 2011; 144(5): 646-674.
21. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 2009; 8(7): 579-591.
22. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol, 2005; 205(2): 275-292.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12(4): 252-264.
24. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy and chemotherapy. Nat Rev Clin Oncol, 2018; 15(7): 382-394.
25. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med, 2006; 354(17): 1813-1826.
26. Bibault JE, Giraud P, Burgun A. Big data and machine learning in radiation oncology and cancer care. Lancet Oncol, 2016; 17(4): e148-e160.
27. Kannan G, Anitha R, Rani NV. Role of clinical pharmacists in oncology patient care. Int J Clin Pharm, 2021; 43(5): 1250-1258.
28. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer, 2012; 12(4): 278-287.
29. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoiesis-stimulating agents in patients with cancer. Cochrane Database Syst Rev, 2019; 1: CD003407.
30. Lyman GH, Dale DC. Prevention of febrile neutropenia in patients receiving chemotherapy. N Engl J Med, 2017; 377(12): 1131-1141.